GH: Total Utang marang Modal Guardant Health, Inc.

Logo perusahaan publik Guardant Corp (GH)

Guardant Health, Inc. (GH) is advancing liquid biopsy technology, where test costs are plummeting due to scalability following FDA approval and the development of AI algorithms. The business relies on successful clinical trials and government programs, while laboratory automation via robotics accelerates DNA sequencing. This chart of stock quotes confirms these data, with the individual debt-to-equity ratio standing at 0.00.

GH: Utang marang Modal Guardant Health 04.07.2022 - 29.10.2026

Guardant Corp - rincian analitis lan metrik utama (GH)

- rega lan prakiraan konsensus rega:
Bagan rega Guardant Health|GH - Prakiraan gabungan firma investasi
- informasi kapitalisasi pasar:
Kapitalisasi pasar Guardant Health|GH - Rega Nyata Tumbas Perusahaan Kanthi Wutuh
- indikator kapitalisasi buku:
Nilai Buku saben Saham Guardant Health|GH - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku guardanthealth.com|GH - Nilai Agregat Aset
- data liabilitas lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas Guardant Health, Inc.|GH - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Guardant Health, Inc.|GH - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Guardant Health|GH - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Guardant Health
Analisis dhasar perusahaan:GH, Guardant Health
Produk merek Guardant Corp

The financial stability of Guardant Health, Inc. (GH) is determined by the balance between the aggressive development of its liquid biopsy R&D pipeline and its debt load. By analyzing the history of the total debt-to-equity ratio, an investor can see the proportion of borrowed funds to net assets, which determines the degree of financial leverage and the risk of default during market shocks. An increase in this ratio may accelerate the expansion of innovations, but it requires alignment with the pace of the business's capitalization.

Perusahaan pesaing

Utang marang Ekuitas Caris Life Sciences|Rasio Utang marang Ekuitas VCYT (Veracyte Inc)|Total Utang marang Modal CELC|Rasio Total Utang marang Ekuitas GRAIL Bio GRAL|Total Utang marang Modal MYGN (Myriad Genetics, Inc.)|castlebiosciences.com (CSTL) - Utang marang Modal|BNR - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi VNRX (VolitionRx Limited)|BDSX (Biodesix Corp) - Rasio Total Utang marang Ekuitas|Precipio Inc - Rasio Kabeh Utang marang Dana Pribadi|CHEK (Check-Cap Ltd) - Total Utang marang Modal|Total Utang marang Modal Mainz Biomed NV|Utang marang Ekuitas OncoCyte (OCX)